StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals Research by Year

Research — Outsourced services ex-lab supplies (FY2013–FY2018, $M) ($M)

Vertex Pharmaceuticals Research: $38.8M in FY2018, down 1.8% from a year earlier. No newer figure appears in the documents we track.

Latest, FY2018
38.8
Period ended Dec 31, 2018
Change on a year earlier
-1.8%
39.5 in FY2017
History
6 years
Since FY2013
Sources
4
Documents cited below

Where the FY2018 figure comes from

“|| Outsourced services | 38,777 | 39,497 | 33,682 | (720 | ) | (2 | )% | 5,815 | 17 | %”

Source: Form 10-K (a201810k-main.htm, filed 2019-02-13) ↗

Reported in Form 10-Q / 10-K MD&A (Research Expenses Disaggregation Table).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedResearch — Outsourced services ex-lab supplies (FY2013–FY2018, $M) ($M)Year on yearSource
FY2018Dec 31, 201838.8-1.8%Form 10-K (a201810k-main.htm, filed 2019-02-13) ↗
FY2017Dec 31, 201739.5+17.2%Form 10-K (a201810k-main.htm, filed 2019-02-13) ↗
FY2016Dec 31, 201633.7+39.3%Form 10-K (a201810k-main.htm, filed 2019-02-13) ↗
FY2015Dec 31, 201524.2+39.1%Form 10-K (a201710k-main.htm, filed 2018-02-15) ↗
FY2014Dec 31, 201417.4-13.9%Form 10-K (a201610k-main.htm, filed 2017-02-23) ↗
FY2013Dec 31, 201320.2–Form 10-K (a201510k-main.htm, filed 2016-02-16) ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals Research ($M), annual FY2013–FY2018 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/rd-res-outsourced-pure

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.